Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
Key facts
- Who runs it
- Yale University
- Where
- New Haven, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Dec 2025
- Expected to end
- Jun 2030
- Type of study
- Observational, 2 groups
- Treatments tested
- Blood draw to measure the levels of dd-cf DNA
- Record updated
- 6 November 2025
- Why it stopped
- Protocol was not approved by the sponsor; therefore PI not moving forward with this study.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who cannot take part
- Multiorgan transplantation
- Less than 3 years from transplantation
- Life expectancy <1 year due to non-cardiac conditions
- Patient appears unlikely or unable to participate in the required study procedures, as assessed by the study PI, study coordinator, or designee (ex: clinically-significant psychiatric, addictive, or neurological disease)
- Evidence of moderate to large area of ischemia on the PET
Other criteria
- Potential subjects must meet all of the following criteria to be eligible for inclusion in the study:
- General Inclusion Criteria:
- The patient is over 18 years of age
- The patient underwent orthotopic heart transplantation and is undergoing routine cardiac allograft vasculopathy (CAV) surveillance with PET
- The patient has no evidence of cardiogenic shock
- The patient has no evidence of acute rejection
- The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC); Potential subjects will be excluded if any of the following conditions apply:
Where in United States
- Yale New Haven HealthNew Haven, United States
About the trial
What the trial wants to find out
The goal of this research study is to understand if a blood test in people who have had heart transplants can detect and predict the following:
Read full original descriptionShow less
* Blockages in the small blood vessels of the heart. * Whether small blockages can turn into more severe blockages in the future.
Participants will undergo blood draws once every 3 months in the first year of the study (4 blood draws total, taking 15 minutes each) and their medical records will be reviewed for 3 years after the date they are enrolled in the study.
The 2 groups in the trial
- Low MFR (less than or equal to 1.5)
Subjects who are found to have a low MFR of less than or equal to 1.5.
Treatment: Blood draw to measure the levels of dd-cf DNA
- Normal MFR (greater than 1.5)
Subjects who are found to have normal MFR of greater than 1.5.
Treatment: Blood draw to measure the levels of dd-cf DNA
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The DEPICT Prospective Study: Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury as Assessed by Donor Derived Cell Free DNA Post Transplantation
- Record updated
- 6 November 2025